News Media Group, Inc. and Digital Lifestyle Expert Mario Armstrong Highlight Spring Tech Trends in a National Satellite Media Tour
West Palm Beach, Florida--(Newsfile Corp. - April 2, 2025) - News Media Group, Inc. conducted a strategic satellite media tour (SMT) and partnered with leading tech brands. Spring is the perfect time for a fresh start-not just for the home, but for the digital world too. As the season of renewal begins, it's time to declutter, organize, and optimize tech habits.
Digital Lifestyle Expert Mario Armstrong lead the SMT while conducting live and taped interviews from a New York City studio. Armstrong shared expert tips and innovative ideas to help reset and recharge with new spring tech, including the Anker SOLIX F3800 Plus, the World Elite Mastercard, the Epson EcoTank® ET-3850, Amazfit Active 2 smartwatch, and ASUS Zenbook Duo.
]
A recap of the spring tech roundup along with details can be found on IntheNews.tv. Brands featured in the SMT included:
The Anker SOLIX F3800 Plus Portable Power Station is designed as the optimal solution for whole-home backup power, particularly during extreme weather outages and rolling blackouts.
Mastercard Your World or World Elite Mastercard helps guard against identity theft and fraudulent purchases.
The Epson EcoTank ET-3850 cartridge-free Supertank printer can be a fast and easy-to-use solution for upgrading family tech this spring.
The Amazfit Active 2 combines style and performance with a sleek stainless steel body and a 1.32-inch AMOLED display at 2,000 nits brightness.
The ASUS Zenbook DUO — a dual-screen laptop with two 14-inch OLED touchscreens, a detachable full-size Bluetooth® magnetic keyboard that charges when attached, and a built-in kickstand.
Media Contact Details:
President
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
3 hours ago
- CNBC
Earnings playbook: Disney and Advanced Micro Devices lead another busy week of reports
The busiest week of earnings has passed, but there are still dozens of key reports still to come that could shake up Wall Street. About 120 S & P 500 companies are scheduled to post their latest earnings. Among them are Disney , Advanced Micro Devices and Dow Jones Industrial Average member Pfizer . Those come after investors last week got quarterly reports from megacap names including Microsoft , Apple , Amazon and Meta Platforms . Roughly two-thirds of the companies in the S & P 500 index have posted quarterly results, with more than 82% exceeding earnings expectations, according to FactSet. Take a look at CNBC Pro's breakdown of what to expect in this week's key reports. All times are ET. Tuesday Pfizer is set to report earnings before the bell. A call is scheduled for 10 a.m. Last quarter: PFE topped expectations as it expanded cost-cutting efforts . This quarter: Analysts expect the pharmaceutical giant to report a slight year-over-year earnings decline, according to LSEG. What to watch: Investors will look for guidance around President Donald Trump's push to lower drug prices — and how that could affect Pfizer's future earnings. The earnings call will likely focus on "RFK Jr and possible risks to vaccines; [and] obesity franchise aspirations and/or other early pipeline opportunities like PFE's next-gen PCV vaccines," BofA analyst Tim Anderson said last month, referring to the Secretary of Health and Human Services. What history shows: Pfizer has a strong track record of exceeding earnings estimates, with the company's bottom line beating expectations 87% of the time, according to Bespoke Investment Group. AMD is set to report earnings after the close, followed by a conference call at 5 p.m. Last quarter: AMD beat on earnings but said it would take a $1.5 billion revenue hit due to restrictions on sales of chips to China. This quarter: Analysts polled by LSEG expect a mixed quarter, with earnings forecast to have dropped nearly 30% year over year, while revenue is anticipated to have grown more than 25%. What to watch: "We see an upside bias for FQ2 (June) results driven by both PC and server" demand, wrote UBS analyst Tim Arcuri on July 28, who rates AMD a buy. "Investors should, however, not expect any quantitative data center GPU commentary for next year as it is probably still too early for AMD to talk about next year other than to say that it feels very good about growth," he added, referring to graphics processing units. What history shows: AMD has fallen after two of the last three earnings releases, including a 6.3% slide after Q4 results came out and an 11% slump following mixed Q3 figures. Super Micro Computer is set to report earnings postmarket. Management's conference call with analysts and institutional investors is slated for 5 p.m. Last quarter: SMCI issued weak guidance, citing " economic uncertainty and tariff impacts ." This quarter: The data center company is expected to post a steep, year-over-year decline in earnings, LSEG data shows. What to watch: JPMorgan analyst Samik Chatterjee placed SMCI on "negative catalyst watch" ahead of these forthcoming earnings, noting "upside in relation to AI demand drivers is likely to be offset by margin pressures stemming from an increasingly competitive landscape, driving downside to the premium valuation multiple SMCI shares are currently trading at." What history shows: According to Bespoke, Super Micro only beats earnings estimates 64% of the time. However, the stock averages a 2.3% advance when the company reports its latest financials. Wednesday Disney is set to report earnings before the bell, followed by a call at 8:30 a.m. Last quarter: DIS climbed on a surprise uptick in streaming subscribers . This quarter: Analysts anticipate the theme park and media giant will report year-over-year earnings growth of about 7%, per LSEG. What to watch: Disney shares have struggled recently, losing more than 5% in the past month, while the S & P 500 is up slightly. Can this report put the House of Mouse back on track? What history shows: Disney earnings have topped earnings expectations in seven of the last eight quarters, per Bespoke. Thursday Eli Lilly is set to report earnings premarket, with a call slated for 8:30 a.m. Last quarter: LLY posted a 45% sales surge on strong demand for weight loss drugs. This quarter: Analysts polled by LSEG expect the Indianapolis-based drugmaker to reveal earnings growth of around 40%. What to watch: Investors will look for continued momentum out of Eli Lilly's Mounjaro weight loss drug. Last week, Lilly said Mounjaro has shown similar heart health benefits in a head-to-head trial with diabetes drug Trulicity, also made by Lilly. What history shows: Bespoke data shows Lilly beats Wall Street expectations 66% of the time. However, the stock doesn't perform well on earnings days, averaging a 0.2% decline.
Business Upturn
21 hours ago
- Business Upturn
HIMS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Hims To Contact Them To Discuss Their Options If you purchased or acquired securities in Hims between April 29, 2025 and June 23, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ('Hims & Hers' or the 'Company') (NYSE:HIMS) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Hims securities between April 29, 2025 and June 23, 2025, both dates inclusive (the 'Class Period'). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose to investors: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;' (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Additionally, the Complaint alleges that Defendants made false and/or misleading statements, as well as failed to disclose material facts, including that: (1) the communication between Hims and the pharmaceutical company Novo Nordisk A/S ('Novo') would facilitate a long-term collaboration that would ensure continued access to the weight-loss drug Wegovy for Hims subscribers; (2) Novo approved of Hims' offerings of compounded semaglutide products under the 'personalization' exception; (3) branded Wegovy would be offered alongside compounded semaglutide options on the Hims platform, thereby expanding user choice; and (4) Defendants made positive statements abou the Novo partnership and Hims users' ongoing access to Wegovy alongside compounded semaglutide products. If you purchased or otherwise acquired Hims & Hers shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, Walker, Passmore, Esq.(212) 355-4648 [email protected]
Business Insider
a day ago
- Business Insider
MRNA Earnings: Moderna Stock Slumps 10% on Lower Covid Vaccine Demand
Shares in drug giant Moderna (MRNA) plummeted nearly 10% today after it reported a drop in Q2 sales. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The company reported earnings for the period of -$2.13, beating expectations of -$3.03 but also recorded a 41.1% drop in year-over-year sales to $142 million. However, that still beat forecasts of $128.3 million. Sentiment Hit Investor sentiment was also hit by the company dropping its revenue guidance for the full year to $1.85 billion at the midpoint from $2 billion, a 7.5% decrease. It blamed the 'timing of shipments.' The decline was primarily driven by lower Spikevax COVID vaccine sales, which totaled $114 million in the quarter. Moderna said demand is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons as the vaccine continues to transition into a seasonal respiratory product. It also reported 'negligible' RSV vaccine mRESVIA® sales in the second quarter of 2025. The figures continue Moderna's difficult year in comparison with its peers – see below. 'In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine efficacy data and expanded our commercial portfolio with three new U.S. FDA approvals to drive future sales growth,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'Looking forward, we have important catalysts over the next six months across our infectious disease and oncology programs that will help us deliver on the promise of our mRNA platform for patients.' Future Hopes This includes Intismeran autogene, a personalized cancer therapy which is being developed in collaboration with Merck (MRK). This includes two non-small cell lung cancer Phase 3 studies and Phase 2 studies for high-risk muscle invasive and high-risk non-muscle invasive bladder cancer. Cost of sales for 2025 is expected to be approximately $1.2 billion. Full-year 2025 research and development expenses are anticipated to be $3.6 to $3.8 billion, lowered from previous expectations of approximately $4.1 billion. Year-end cash and investments for 2025 are projected to be approximately $6 billion. Recently, Moderna announced an organizational restructuring that will reduce its global workforce by approximately 10%. The company anticipates a total headcount of less than 5,000 by the end of the year. Better news came today for the group after Pfizer (PFE) and its German partner BioNTech (BNTX) lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
